Covidien launches performance excipient.

Covidient, a leading global provider of healthcare products, has announced that its Mallinckrodt Baker business unit is introducing PanExcea MHC300G, a performance excipient. PanExcea MHC300G is a homogeneous particle that serves as a filler, binder and disintegrant for immediate release applications. Manufactured using novel particle engineering technology, the granular spherical excipient provides multifunctional performance capabilities that enable efficient and cost-effective drug development and manufacturing. The excipient lowers the total cost of ownership for the drug formulator by facilitating direct compression of even the most difficult Active Pharmaceutical Ingredients (APIs). It offers extensive API compatibility and variable API load capability to increase formulation flexibility. PanExcea MHC300G, which can be used as a building block or as a complete excipient, provides formulation development flexibilities and efficiencies, and it also enables implementation of Quality by Design initiatives.

"J.T.Baker PanExcea performance excipients are Mallinckrodt Baker's entry into the global performance excipient marketplace. We are proud to introduce this new technology, which allows our customers to simplify drug formulation development and reduce supply chain complexities," said Patrick Henry, global marketing manager, pharmaceutical excipients for Mallinckrodt Baker. Customers interested in learning more about the new PanExcea product line should visit www.mallbaker.com/panexcea to request a qualification sample. Mallinckrodt Baker will be featuring the new PanExcea product line at its booth at CPhl.

[ILLUSTRATION OMITTED]